{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:35:43Z","timestamp":1790933743799,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T00:00:00Z","timestamp":1280966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T00:00:00Z","timestamp":1280966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1038\/leu.2010.157","type":"journal-article","created":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T09:41:59Z","timestamp":1281001319000},"page":"1760-1768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells"],"prefix":"10.1038","volume":"24","author":[{"given":"R","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,8,5]]},"reference":[{"key":"BFleu2010157_CR1","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","volume":"112","author":"TW LeBien","year":"2008","unstructured":"LeBien TW, Tedder TF . B lymphocytes: how they develop and function. Blood 2008; 112: 1570\u20131580.","journal-title":"Blood"},{"key":"BFleu2010157_CR2","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1038\/sj.onc.1210365","volume":"26","author":"B Bonavida","year":"2007","unstructured":"Bonavida B . Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo\/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007; 26: 3629\u20133636.","journal-title":"Oncogene"},{"key":"BFleu2010157_CR3","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1038\/sj.onc.1210376","volume":"26","author":"B Coiffier","year":"2007","unstructured":"Coiffier B . Rituximab therapy in malignant lymphoma. Oncogene 2007; 26: 3603\u20133613.","journal-title":"Oncogene"},{"key":"BFleu2010157_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMra0708875","volume":"359","author":"B Cheson","year":"2008","unstructured":"Cheson B, Leonard JP . Monoclonal antibody therapy for B-cell non-Hodgkin\u2019s lymphoma. N Engl J Med 2008; 359: 613\u2013626.","journal-title":"N Engl J Med"},{"key":"BFleu2010157_CR5","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith MR . Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359\u20137368.","journal-title":"Oncogene"},{"key":"BFleu2010157_CR6","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","volume":"21","author":"JD Hainsworth","year":"2003","unstructured":"Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21: 1746\u20131751.","journal-title":"J Clin Oncol"},{"key":"BFleu2010157_CR7","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/cncr.21776","volume":"106","author":"DA Thomas","year":"2006","unstructured":"Thomas DA, Faderl S, O\u2019Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 1569\u20131580.","journal-title":"Cancer"},{"key":"BFleu2010157_CR8","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1182\/blood-2008-09-177469","volume":"113","author":"NA Johnson","year":"2009","unstructured":"Johnson NA, Boyle M, Bashashati A, Leach S, Brooks-Wilson A, Sehn LH et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 2009; 113: 3773\u20133780.","journal-title":"Blood"},{"key":"BFleu2010157_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1046\/j.1365-2141.2002.03843.x","volume":"119","author":"GA Kennedy","year":"2002","unstructured":"Kennedy GA, Tey S-K, Cobcroft R, Marlton P, Cull G, Grimmett K et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol 2002; 119: 412\u2013416.","journal-title":"Br J Haematol"},{"key":"BFleu2010157_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.3324\/haematol.10255","volume":"92","author":"AJ Ferreri","year":"2007","unstructured":"Ferreri AJ, Dognini GP, Verona C, Patriarca C, Doglioni C, Ponzoni M . Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma. Haematologica 2007; 92: e1\u2013e2.","journal-title":"Haematologica"},{"key":"BFleu2010157_CR11","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","volume":"113","author":"J Hiraga","year":"2009","unstructured":"Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009; 113: 4885\u20134893.","journal-title":"Blood"},{"key":"BFleu2010157_CR12","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1056\/NEJMra072067","volume":"358","author":"ME Esteller","year":"2008","unstructured":"Esteller ME . Epigenetics in cancer. N Engl J Med 2008; 358: 1148\u20131159.","journal-title":"N Engl J Med"},{"key":"BFleu2010157_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","volume":"1","author":"S Ropero","year":"2007","unstructured":"Ropero S, Esteller M . The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1: 19\u201325.","journal-title":"Mol Oncol"},{"key":"BFleu2010157_CR14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nrm2346","volume":"9","author":"X-J Yang","year":"2008","unstructured":"Yang X-J, Seto E . The Rpd3\/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008; 9: 206\u2013218.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFleu2010157_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1535-6108(04)00114-X","volume":"5","author":"P Zhu","year":"2004","unstructured":"Zhu P, Martin E, Mengwasser J, Schlag P, Janssen K-P, Gottlicher M . Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004; 5: 455\u2013463.","journal-title":"Cancer Cell"},{"key":"BFleu2010157_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/sj.onc.1209072","volume":"25","author":"Y Kobayashi","year":"2006","unstructured":"Kobayashi Y, Ohtsuki M, Murakami T, Kobayashi T, Sutheesophon K, Kitayama H et al. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. Oncogene 2006; 25: 512\u2013524.","journal-title":"Oncogene"},{"key":"BFleu2010157_CR17","doi-asserted-by":"publisher","first-page":"30673","DOI":"10.1074\/jbc.M109.042242","volume":"284","author":"T Wada","year":"2009","unstructured":"Wada T, Kikuchi J, Nishimura N, Shimizu R, Kitamura T, Furukawa Y . Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors. J Biol Chem 2009; 284: 30673\u201330683.","journal-title":"J Biol Chem"},{"key":"BFleu2010157_CR18","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1158\/0008-5472.CAN-05-4186","volume":"66","author":"P Maiso","year":"2006","unstructured":"Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutlerrez N et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006; 66: 5781\u20135789.","journal-title":"Cancer Res"},{"issue":"3","key":"BFleu2010157_CR19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1182\/blood-2009-07-235663","volume":"116","author":"J. Kikuchi","year":"2010","unstructured":"Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood, e-pub ahead of print 29 March 2010; doi:10.1182\/blood-2009-07-235663.","journal-title":"Blood"},{"key":"BFleu2010157_CR20","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","volume":"26","author":"WS Xu","year":"2007","unstructured":"Xu WS, Parmigiani RB, Marks PA . Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541\u20135552.","journal-title":"Oncogene"},{"key":"BFleu2010157_CR21","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/sj.jid.5701216","volume":"128","author":"T Murakami","year":"2008","unstructured":"Murakami T, Sato A, Chun NAL, Hara M, Naito Y, Kobayashi Y et al. Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. J Invest Dermatol 2008; 128: 1506\u20131516.","journal-title":"J Invest Dermatol"},{"key":"BFleu2010157_CR22","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1182\/blood-2007-07-101311","volume":"111","author":"S Diermayr","year":"2008","unstructured":"Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008; 111: 1428\u20131436.","journal-title":"Blood"},{"key":"BFleu2010157_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/jcp.20235","volume":"203","author":"K Sutheesophon","year":"2005","unstructured":"Sutheesophon K, Nishimura N, Kobayashi Y, Furukawa Y, Kawano M, Itoh K et al. Involvement of the tumor necrosis factor (TNF)\/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). J Cell Physiol 2005; 203: 387\u2013397.","journal-title":"J Cell Physiol"},{"key":"BFleu2010157_CR24","doi-asserted-by":"publisher","first-page":"7317","DOI":"10.1158\/0008-5472.CAN-06-0680","volume":"66","author":"A Lundqvist","year":"2006","unstructured":"Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredin D, Berg M et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006; 66: 7317\u20137325.","journal-title":"Cancer Res"},{"key":"BFleu2010157_CR25","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood.V96.12.3847","volume":"96","author":"T Maeda","year":"2000","unstructured":"Maeda T, Towatari M, Kosugi H, Saito H . Up-regulation of costimulatory\/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 2000; 96: 3847\u20133856.","journal-title":"Blood"},{"key":"BFleu2010157_CR26","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/nar\/gkj462","volume":"34","author":"M Gialitakis","year":"2006","unstructured":"Gialitakis M, Kretsovali A, Spilianakis C, Kravariti L, Mages J, Hoffmann R et al. Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A. Nucleic Acids Res 2006; 34: 765\u2013772.","journal-title":"Nucleic Acids Res"},{"key":"BFleu2010157_CR27","first-page":"743","volume":"19","author":"O Suzuki","year":"2008","unstructured":"Suzuki O, Abe M . Cell surface N-glycosylation and sialylation regulate galectin-3-induced apoptosis in human diffuse large lymphoma. Oncol Rep 2008; 19: 743\u2013748.","journal-title":"Oncol Rep"},{"key":"BFleu2010157_CR28","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1182\/blood-2006-04-017921","volume":"108","author":"R Stein","year":"2006","unstructured":"Stein R, Qu Z, Chen S, Solis D, Hansen HJ, Goldenberg DM . Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood 2006; 108: 2736\u20132744.","journal-title":"Blood"},{"key":"BFleu2010157_CR29","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1634\/stemcells.2007-0207","volume":"25","author":"J Kikuchi","year":"2007","unstructured":"Kikuchi J, Shimizu R, Wada T, Ando H, Nakamura M, Ozawa K et al. E2F-6 suppresses growth-associated apoptosis of human hematopoietic progenitor cells by counteracting proapoptotic activity of E2F-1. Stem Cells 2007; 25: 2439\u20132447.","journal-title":"Stem Cells"},{"key":"BFleu2010157_CR30","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1182\/blood-2004-09-3533","volume":"105","author":"SD Gillies","year":"2005","unstructured":"Gillies SD, Lan Y, Williams S, Carr F, Forman S, Raubitschek A et al. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 2005; 105: 3972\u20133978.","journal-title":"Blood"},{"key":"BFleu2010157_CR31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood.V96.1.282","volume":"96","author":"F Bertolini","year":"2000","unstructured":"Bertolini F, Fusetti L, Mancuso P, Gobbi A, Corsini C, Ferrucci PF et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD\/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood 2000; 96: 282\u2013287.","journal-title":"Blood"},{"key":"BFleu2010157_CR32","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1517\/17425250902911455","volume":"5","author":"PM Haddad","year":"2009","unstructured":"Haddad PM, Das A, Ashfaq M, Wieck A . A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol 2009; 5: 539\u2013551.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"BFleu2010157_CR33","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1182\/blood-2003-12-4333","volume":"104","author":"A Kuendgen","year":"2004","unstructured":"Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004; 104: 1266\u20131269.","journal-title":"Blood"},{"key":"BFleu2010157_CR34","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cncr.21552","volume":"106","author":"A Kuendgen","year":"2006","unstructured":"Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006; 106: 112\u2013119.","journal-title":"Cancer"},{"key":"BFleu2010157_CR35","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/00007691-199210000-00013","volume":"14","author":"JE Tisdale","year":"1992","unstructured":"Tisdale JE, Tsuyuki RT, Oles KS, Penry JK . Relationship between serum concentration and dose of valproic acid during monotherapy in adult outpatients. Ther Drug Monitor 1992; 14: 416\u2013423.","journal-title":"Ther Drug Monitor"},{"key":"BFleu2010157_CR36","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2004-05-1693","volume":"105","author":"JC Bryd","year":"2005","unstructured":"Bryd JC, Marcucci G, Parthum MR, Xiao JJ, Klisovic RB, Moran M et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105: 959\u2013967.","journal-title":"Blood"},{"key":"BFleu2010157_CR37","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1200\/JCO.2006.06.4964","volume":"24","author":"M Fouladi","year":"2006","unstructured":"Fouladi M, Furman WL, Chin T, Freeman III BB, Dudkin L, Stewart CF et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a children's oncology group report. J Clin Oncol 2006; 24: 3678\u20133685.","journal-title":"J Clin Oncol"},{"key":"BFleu2010157_CR38","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1158\/1078-0432.CCR-07-0318","volume":"14","author":"VN Klimek","year":"2008","unstructured":"Klimek VN, Fircanis S, Maslak P, Guernah I, Baum M, Wu N et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008; 14: 826\u2013832.","journal-title":"Clin Cancer Res"},{"key":"BFleu2010157_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000089471","volume":"115","author":"K Sutheesophon","year":"2006","unstructured":"Sutheesophon K, Kobayashi Y, Takatoku M, Ozawa K, Kano Y, Furukawa Y . Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol 2006; 115: 78\u201390.","journal-title":"Acta Haematol"},{"key":"BFleu2010157_CR40","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","volume":"98","author":"RL Piekarz","year":"2001","unstructured":"Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001; 98: 2865\u20132868.","journal-title":"Blood"},{"key":"BFleu2010157_CR41","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1182\/blood-2003-01-0055","volume":"102","author":"I Jilani","year":"2003","unstructured":"Jilani I, O\u2019Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003; 102: 3514\u20133520.","journal-title":"Blood"},{"key":"BFleu2010157_CR42","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1182\/blood-2008-01-133108","volume":"112","author":"R Lapalombella","year":"2008","unstructured":"Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008; 112: 5180\u20135189.","journal-title":"Blood"},{"key":"BFleu2010157_CR43","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1016\/S0021-9258(18)53411-6","volume":"268","author":"C Thevenin","year":"1993","unstructured":"Thevenin C, Lucas BP, Kozlow EJ, Kehrl JH . Cell type- and stage-specific expression of the CD20\/B1 antigen correlates with the activity of a diverged octamer DNA motif present in its promoter. J Biol Chem 1993; 268: 5949\u20135956.","journal-title":"J Biol Chem"},{"key":"BFleu2010157_CR44","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1182\/blood.V90.10.3984","volume":"90","author":"A Himmelmann","year":"1997","unstructured":"Himmelmann A, Riva A, Wilson GL, Lucas BP, Thevenin C, Kehrl JH . PU.1\/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. Blood 1997; 90: 3984\u20133995.","journal-title":"Blood"},{"key":"BFleu2010157_CR45","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1101\/gad.7.4.570","volume":"7","author":"LM Corcoran","year":"1993","unstructured":"Corcoran LM, Karvelas M, Nossal GJV, Ye Z-S, Jacks T, Baltimore D . Oct-2, although not required for early B-cell development, is critical for later B-cell maturation and for postnatal survival. Genes Dev 1993; 7: 570\u2013582.","journal-title":"Genes Dev"},{"key":"BFleu2010157_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1532\/IJH97.07028","volume":"85","author":"A Tomita","year":"2007","unstructured":"Tomita A, Hiraga J, Kiyoi H, Ninomiya M, Sugimoto T, Ito M et al. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol 2007; 85: 49\u201357.","journal-title":"Int J Hematol"},{"key":"BFleu2010157_CR47","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1016\/j.molimm.2009.05.001","volume":"46","author":"MN Cruickshank","year":"2009","unstructured":"Cruickshank MN, Fenwick E, Karimi M, Abraham LJ, Ulgiati D . Cell- and stage-specific chromatin structure across the complement receptor 2 (CR2\/CD21) promoter coincide with CBF1 and C\/EBP-\u03b2 binding in B cells. Mol Immunol 2009; 46: 2613\u20132622.","journal-title":"Mol Immunol"},{"key":"BFleu2010157_CR48","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1084\/jem.183.4.1747","volume":"183","author":"JS Maltzman","year":"1996","unstructured":"Maltzman JS, Carman JA, Monroe JG . Transcriptional regulation of the Icam-1 gene in antigen receptor- and phorbol ester-stimulated B lymphocytes: Role for transcription factor EGR1. J Exp Med 1996; 183: 1747\u20131759.","journal-title":"J Exp Med"},{"key":"BFleu2010157_CR49","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/MPH.0b013e3181c29c3c","volume":"32","author":"Y Ikawa","year":"2010","unstructured":"Ikawa Y, Sugimoto N, Koizumi S, Yachie A, Saikawa Y . Dense methylation of types 1 and 2 regulatory regions of the CD10 gene promoter in infant acute lymphoblastic leukemia with MLL\/AF4 fusion gene. J Pediatr Hematol Oncol 2010; 32: 4\u201310.","journal-title":"J Pediatr Hematol Oncol"},{"key":"BFleu2010157_CR50","doi-asserted-by":"publisher","first-page":"5492","DOI":"10.1128\/MCB.18.9.5492","volume":"18","author":"S Kudo","year":"1998","unstructured":"Kudo S . Methyl-CpG-binding protein MeCP2 represses Sp1-activated transcription of the human leukosialin gene when the promoter is methylated. Mol Cell Biol 1998; 18: 5492\u20135499.","journal-title":"Mol Cell Biol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2010157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2010157","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2010157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T13:37:25Z","timestamp":1648733845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2010157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,5]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["BFleu2010157"],"URL":"https:\/\/doi.org\/10.1038\/leu.2010.157","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,5]]},"assertion":[{"value":"12 October 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}